|
Dec 25
|
Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025?
|
|
Dec 24
|
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
|
|
Dec 24
|
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
|
|
Dec 24
|
Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist
|
|
Dec 24
|
3 No-Brainer Stocks to Buy on the Latest Sell-Off
|
|
Dec 24
|
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘Their Painkiller Equaled The Placebo. And That’s Just A Shame’
|
|
Dec 23
|
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
|
|
Dec 23
|
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
|
|
Dec 22
|
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
|
|
Dec 22
|
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
|
|
Dec 21
|
Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
|
|
Dec 21
|
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
|
|
Dec 21
|
My Top 10 Stocks to Buy for 2025
|
|
Dec 20
|
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
|
|
Dec 20
|
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
|
|
Dec 20
|
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
|
|
Dec 20
|
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
|
|
Dec 20
|
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
|
|
Dec 19
|
S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat
|
|
Dec 19
|
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug
|